

Instructions for Authors 2021

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

AR provides for the prompt print and online publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work (without supplementary data), and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work or before the Acknowledgements); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors’ contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures (graphs and photographs). All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Figures should be prepared at a width of 8 or 17cm with eligible symbols, lettering and numbers. The number of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Each table may have 2-10 vertical columns. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dagleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if

applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iar@iar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 5 days from submission, the author should contact the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for peer-review (single-blind) in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
 5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
 6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and Discussion should not be combined into one section.
 - Results given in figures should not be repeated in tables.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably in red. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
 9. All Authors will be asked to supply author contribution and conflict of interest forms.
 10. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.
 (Rejection rate (2020): 68%).
 11. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
 12. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
 13. Authors who wish to organize and edit a special issue on a particular topic should contact the Managing Editor.
 14. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2021 – International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Esophageal Adenocarcinoma Metastasizing to a Solitary Fibrous Tumor: An Unprecedented Case of Tumor-to-tumor Metastasis. U. JOGIAT, C. GRANT, E.L.R. BEDARD, K. AU, R. MAGLANTAY, D. WILLIAMS (Edmonton, AB, Canada).....	5835
Aggressive Plasmablastic Myeloma With Extramedullary Cord Compression and Hyperammonemic Encephalopathy: Case Report and Literature Review. K. DAH, J.L. LAVEZO, F. DIHOWM (El Paso, TX, USA)	5839
A Case Report of Metachronous Multiple Adenosquamous Carcinoma of the Colon Over-expressing PD-L1 and a Literature Review. S. AKAHOSHI, K. YAMAMURA, Y. KOMOHARA, D. YOSHII, E. ODA, N. SATO, H. YUKI, K. YUKIMURA, T. BEPPU (Kumamoto, Japan)	5847
Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy. Y. ADACHI, K. YAMAMURA, S. YUMOTO, T. HIGASHI, H. ISHIODORI, S. HONDA, Y. HARA, K. MATSUMURA, E. ODA, S. AKAHOSHI, H. YUKI, H. MIYAMOTO, K. DOI, T. BEPPU (Nobeoka; Yamaga; Kumamoto, Japan)	5855
Errata	5863

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. Y. SHIMODA, T. YOSHIDA, M. SHIRASAWA, T. MIZUNO, H. JO, Y. MATSUMOTO, Y. SHINNO, Y. OKUMA, Y. GOTO, H. HORINOUCI, N. YAMAMOTO, Y. YATABE, Y. OHE, N. MOTOI (<i>Tokyo, Japan</i>).....	5739
Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC). P. PALACKA, J. SLOPOVSKY, J. OBERTOVA, M. CHOVANEC, K. REJLEKOVA, Z. SYCOVA-MILA, B. KOLLARIK, J. MARDIAK, M. MEGO (<i>Bratislava, Slovak Republic</i>).....	5749
Prognostic Factors of Potential Early Recurrence of Hypopharyngeal Carcinoma. D. BABA, C. FUSHIMI, K. HANYU, T. MASUBUCHI, Y. TADA, K. MURA (<i>Chiba; Tokyo, Japan</i>).....	5761
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma. T. YUMIOKA, M. HONDA, R. SHIMIZU, S. TERAOKA, N. YAMAGUCHI, B. KAWAMOTO, H. IWAMOTO, S. MORIZANE, K. HIKITA, A. TAKENAKA (<i>Tottori, Japan</i>).....	5767
Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma. S. OMIYA, S. KOMATSU, M. KIDO, K. KURAMITSU, H. GON, K. FUKUSHIMA, T. URADE, S. SO, K. SOFUE, Y. YANO, Y. SAKAI, H. YANAGIMOTO, H. TOYAMA, T. AJIKI, T. FUKUMOTO (<i>Kobe, Japan</i>).....	5775
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma. T. NARUSE, S. YANAMOTO, M. OTSURU, N. YAMAKAWA, T. KIRITA, Y. SHINTANI, T. MATSUMURA, M. OKURA, M. SASAKI, Y. OTA, S.-I. YAMADA, H. KURITA, M. UMEDA (<i>Nagasaki; Kashihara; Wakayama; Osaka; Matsusaka; Isehara; Matsumoto, Japan</i>).....	5785
Radiation Pneumonitis After Volumetric Modulated Arc Therapy for Non-small Cell Lung Cancer. M. FUJIWARA, H. DOI, M. IGETA, H. SUZUKI, K. KITAJIMA, M. TANOOKA, T. ISHIDA, T. WAKAYAMA, T. YOKOI, K. KURIBAYASHI, T. KIJIMA, M. HASHIMOTO, N. KONDO, S. MATSUMOTO, S. HASEGAWA, N. KAMIKONYA, K. YAMAKADO (<i>Nishinomiya, Japan</i>).....	5793
Venous Invasion and Perineural Invasion as Upstaging and Poor Prognostic Factors in N0 Gastric Cancers. K. CHANG, B. SONG, I.-G. DO, D.-H. KOO, H.W. LEE, B.H. SON, C.H. YOO, K. KIM (<i>Seoul; Changwon, Republic of Korea</i>).....	5803
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. T. KATO, A. NAGAHARA, N. KAWAMURA, W. NAKATA, T. SODA, K. MATSUZAKI, K. HATANO, A. KAWASHIMA, T. UJIKE, R. IMAMURA, K. NISHIMURA, S. TAKADA, M. TSUJIHATA, S. YAMAGUCHI, T. TAKAO, Y. NAKAI, M. NAKAYAMA, N. NONOMURA, M. UEMURA (<i>Osaka, Japan</i>).....	5811
Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes. N. IMAI, S. YOKOYAMA, K. YAMAMOTO, T. ITO, Y. ISHIZU, T. HONDA, M. ISHIGAMI (<i>Nagoya, Japan</i>).....	5817
A Novel Predictive Model for Anastomotic Leakage in Colorectal Cancer Using Auto-artificial Intelligence. J. MAZAKI, K. KATSUMATA, Y. OHNO, R. UDO, T. TAGO, K. KASAHARA, H. KUWABARA, M. ENOMOTO, T. ISHIZAKI, Y. NAGAKAWA, A. TSUCHIDA (<i>Tokyo, Japan</i>).....	5821
Risk Factors Associated With Unplanned Acute Care in Outpatient Chemotherapy With Oral Anticancer Drugs as Monotherapy or Combination Therapy With Injectable Anticancer Drugs. K. KAWASUMI, Y. KAWANO, A. KUJIRAI, Y. MANO, R. MATSUI, A. MAEDA-MINAMI, Y. YAMAMOTO, K. NEGISHI, S. SHIMADA, M. YAMAGUCHI, M. NAGATA, T. AOYAMA (<i>Chiba; Tokyo, Japan</i>).....	5827

Prognostic Value of <i>EGFR</i> Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. J. SKRICKOVA, M. PESEK, P. OPALKA, L. KOUBKOVA, M. ZEMANOVA, M. HRNCIARIK, J. BLAZEK, M. SVATON, J. KREJCI, H. COUPKOVA, D. DOLEZAL, T. TUZOVA, L. HOLUBEC, P. MAHADEVIA, K. SANDSTROM, P. KUNOVSKI, M. BARINOVA, K. HURDALKOVA, O. FISCHER, M. CERNOVSKA, M. BRATOVA (Brno; Pilsen; Prague; Hradec Kralove; Usti nad Labem; Jihlava; Olomouc, Czech Republic; Raritan, NJ, USA; Stockholm, Sweden; Budapest, Hungary)	5625
Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease. T. SAITO, K. OHNISHI, H. ISHIKAWA, M. NAKAMURA, S. HOSHIAI, H. NUMAJIRI, K.N. MUROFUSHI, M. MIZUMOTO, T. OKUMURA, H. SAKURAI (Tsukuba; Chiba; Tokyo, Japan)	5635
The Clinical Significance of CA19-9 and Tumor Size Ratios for Predicting Prognosis After Conversion Surgery in Patients With Stage IV Gastric Cancer. K. OKUBO, T. ARIGAMI, D. MATSUSHITA, Y. UENOSONO, S. YANAGITA, T. KIJIMA, Y. TSURUDA, M. NODA, K. SASAKI, S. MORI, H. KURAHARA, T. OHTSUKA (Kagoshima, Japan)	5643
Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases. K. FURUKAWA, S. ONDA, T. TANIAI, R. HAMURA, M. YANAGAKI, M. TSUNEMATSU, O. HARUKI, J. YASUDA, T. SAKAMOTO, T. GOCHO, T. IKEGAMI (Tokyo, Japan).....	5651
Pre-pectoral Breast Reconstruction Does Not Affect Early Immunological Response: A BIAL 2.20 Study Subanalysis. G. VANNI, M. PELLICCIARO, A. SADRI, F. TACCONI, M. MATERAZZO (Rome, Italy; London, UK)	5657
Erector Spinae Plane Block Versus Serratus Plane Block in Breast Conserving Surgery: A Randomized Controlled Trial. G. VANNI, G. CAIAZZA, M. MATERAZZO, G. STORTI, M. PELLICCIARO, C. BUONOMO, S. NATOLI, E. FABBI, M. DAURI (Rome, Italy)	5667
Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. Y.B. HAN, J.M. YANG, H.J. KWON, J.-O. LEE, J.S. LEE, J.H. PAIK (Seongnam; Seoul, Republic of Korea)	5677
Clinical Impact of Primary Tumor Site in Stage IV Colorectal Cancer: A Statewide Cohort Study. H. KAWAMURA, M. HONDA, K. TAKIGUCHI, T. KAMIGA, K. SAITO, A. MUTO, S. SHIRASO, N. YAMASHITA, T. IWAO, S. SAJI, K. KONO, S. KONNO (Fukushima; Koriyama; Aizu-Wakamatsu; Shirakawa; Iwaki, Japan)	5693
Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes. J.H. JUNG, S.K. YOON, S.J. YOON, S.H. SHIN, I.W. HAN, J.S. HEO (Seoul, Republic of Korea).....	5703
Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression. Y.-M. NA, J.-S. CHO, M.-H. PARK (Hwasun; Gwangju, Republic of Korea).....	5713
Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions. H. TOKISAWA, T. ARUGA, Y. HONDA, T. ISHIBA, R. YONEKURA, N. IWAMOTO, Y. KUMAKI, S. TOMITA, M. FUJII, Y. TERAOKA (Tokyo, Japan).....	5723
Pretreatment Platelet Count and Neutrophil/Lymphocyte Ratio Are Predictive Markers for Carboplatin Plus Pemetrexed Therapy-induced Thrombocytopenia. M. TAKAHASHI, K. TAKAHASHI, H. KANEDA, T. KAWAGUCHI, K. NAGAYAMA (Osaka, Japan)	5729

Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and <i>Helicobacter pylori</i> Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel® Test. O.-P. KOIVUROVA, R. KOSKELA, T. BLOMSTER, A. ALA-RÄMI, H. LUMME, O. KETTUNEN, J. HUKKANEN, T.J. KARTTUNEN, M. MÄKINEN, J. RONKAINEN, K. SYRJÄNEN (<i>Oulu; Tornio; Kaarina, Finland; Barretos, Brazil</i>).....	5527
Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases. T. TAGO, K. KATSUMATA, R. UDOU, K. KASAHARA, J. MAZAKI, H. KUWABARA, M. ENOMOTO, T. ISHIZAKI, Y. NAGAKAWA, K. SUGIMOTO, T. ITOI, A. TSUCHIDA (<i>Tokyo, Japan</i>).....	5539
Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry. O. VENCLICEK, J. SKRICKOVA, K. BRAT, O. FISCHER, L. HAVEL, M. HRNCIARIK, M. MAREL, P. OPALKA, G. KRAKOROVA, D. ROZSIVALOVA, J. KULTAN, A. MULLEROVA, L. ZARNAYOVA, P. SMICKOVA, M. VASAKOVA, Z. GYORFY, M. JIROUSEK, D. KREJCI, J. KREJCI, P. ZUNA, M. SVATON, K. HRDA, J. DUBA, J. ALAHAKOON, M. SVOBODA, J. SILAR (<i>Brno; Olomouc; Prague; Hradec Kralove; Pilsen, Czech Republic</i>).....	5549
Double Positivity for HPV DNA/P16 ^{INK4a} Does Not Influence Survival of Patients With Oral Squamous Cell Carcinoma. U. ALSHARIF, M. HOFMANN, M. GEBHARD, L. THARUN, D. RADES, P. SIEG, S.G. HAKIM (<i>Lübeck; Dortmund; Marburg, Germany</i>).....	5557
Peritoneal Spread of Low-grade Appendiceal Tumours – 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough. A. RAO, J. MUI, S. BARAT, A.A. MATAR, N. ALZHRANI, D.L. MORRIS (<i>Kogarah, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i>).....	5569
Postoperative Pancreatic Fistula After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Update on Incidence, Risk Factors, Management, and Clinical Sequelae in 1,141 Patients. A. MATAR, T. MEARES, O.M. FISHER, C. GAUCI, A. RAO, M. ALSHAHRANI, N. ALZHRANI, D.L. MORRIS (<i>Sydney, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i>).....	5577
Predictors for Outcome and Complications Related to Urinary Diversion. N. FISCHER, J. ELLINGER, B. KOEDITZ, A. HEIDENREICH, M.A. HOFFMANN (<i>Cologne; Bonn, Germany</i>).....	5585
Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer. L. BLAS, K. IEIRI, M. SHIOTA, S. NAGAKAWA, S. TSUKAHARA, T. MATSUMOTO, E. KASHIWAGI, A. TAKEUCHI, J. INOKUCHI, K.-I. SHIGA, A. YOKOMIZO, M. ETO (<i>Fukuoka, Japan</i>).....	5593
Risk Factors for Complications Following Lateral Pelvic Lymph Node Dissection for Rectal Cancer. D. OKAMOTO, T. MATSUDA, R. SAWADA, H. HASEGAWA, K. YAMASHITA, H. HARADA, H. GOTO, N. URAKAWA, S. KANAJI, T. OSHIKIRI, Y. KAKEJI (<i>Kobe, Japan</i>).....	5599
Safety and Feasibility of Gastrectomy for Gastric Cancer in Patients Receiving Antiplatelet and/or Anticoagulation Treatment. T. AOYAMA, M. NAKAZONO, K. SEGAMI, S. NAGASAWA, K. HARA, H. TAMAGAWA, K. KOMORI, H. SUEMATSU, Y. MAEZAWA, K. KANO, I. HASHIMOTO, T. YAMADA, T. SATO, M. NUMATA, N. YUKAWA, T. OGATA, Y. RINO, T. OSHIMA (<i>Yokohama, Japan</i>).....	5605
Brain Metastasis in Soft Tissue Sarcoma at Initial Presentation. R. ITOGA, M. MATSUOKA, T. ONODERA, I. YOKOTA, K. IWASAKI, S. MATSUBARA, R. HISHIMURA, Y. SUZUKI, A. IWATA, E. KONDO, N. IWASAKI (<i>Sapporo, Japan</i>).....	5611
Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection. S. MASATSUNE, K. KIMURA, S. KASHIWAGI, W. EN, Y. OKAZAKI, K. MAEDA, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>).....	5617

SHH Expression Is Significantly Associated With Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma. P. CIERPIKOWSKI, A. LIS-NAWARA, J. BAR (<i>Wroclaw, Poland</i>)	5405
Simplified Theta-defensin [Ser ^{3,7,12,16}] RTD-2 Analog Is Involved in Proteasomal Degradation Pathway in Breast Cancer. J. PIANKA, N. GRUBA, K. KITOWSKA, K. MIECZKOWSKI, M. WYSOCKA, R. SADEJ, A. LESNER (<i>Gdansk, Poland</i>)	5415
Association of <i>TIMP-2</i> Rs8179090 Genotypes With Lung Cancer Risk in Taiwan. W.-C. LIAO, C.-W. HUANG, T.-C. HSIA, Y.-C. SHEN, W.-S. CHANG, C.-W. TSAI, Y.-C. WANG, M.-C. YIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	5425
SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability. S.A. ROH, Y.H. KWON, J.L. LEE, S.-K. KIM, J.C. KIM (<i>Seoul; Daejeon, Republic of Korea</i>)	5431
BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy. H. SUZUMURA, M. TSURUTA, K. OKABAYASHI, K. SHIGETA, R. SEISHIMA, T. ISHIDA, T. SHIMADA, Y. ASADA, K. KOISHIKAWA, S. AKIMOTO, O. ITANO, H. HASEGAWA, Y. KITAGAWA (<i>Tokyo; Narita; Ichikawa, Japan</i>).....	5445
Zinc Inhibits Cadherin 1 Expression Induced by 1 α ,25-Dihydroxyvitamin D3 in Colon Cancer Cells. M. ISHIZAWA, A. HIRAYU, M. MAKISHIMA (<i>Tokyo; Kanagawa, Japan</i>)	5453
Telmisartan Exerts Cytotoxicity in Scirrhus Gastric Cancer Cells by Inducing G ₀ /G ₁ Cell Cycle Arrest. Y. TSUJIYA, M. YAMAMORI, A. HASEGAWA, Y. YAMAMOTO, M. YASHIRO, N. OKAMURA (<i>Nishinomiya; Osaka, Japan</i>)	5461
Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Y. NOJIMA, K. SHIMIZU, S. SAISHO, A. MAEDA, T. KUROSAKI, K. KUROSE, T. OGA, M. OKA, M. NAKATA (<i>Okayama, Japan</i>)	5469
Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells. R. ISONO, H. TSUBAMOTO, T. UEDA, Y. TAKIMOTO, K. INOUE, K. SAKATA, H. SHIBAHARA, S. NISHIUMI (<i>Nishinomiya, Japan</i>).....	5477
Profiling of Aldehyde Dehydrogenase Isoforms in <i>In Vitro</i> Formed Tumorspheres. I. TSOCHANTARIDIS, G.-P. VOULGARIDOU, A. GIATROMANOLAKI, M.I. KOUKOURAKIS, M.I. PANAYIOTIDIS, A. PAPPA (<i>Alexandroupolis, Greece; Nicosia, Cyprus</i>)	5481
Ideal Nozzle Position During Pressurized Intraperitoneal Aerosol Chemotherapy in an <i>Ex Vivo</i> Model. J. PIAO, S.J. PARK, H. LEE, J. KIM, S. PARK, N. LEE, S.I. KIM, M. LEE, G. SONG, J.C. LEE, H.S. KIM (<i>Seoul; Jinju-si, Republic of Korea</i>).....	5489
Positive Correlation Between the Number of Circulating Tumor Cells in the Pulmonary Vein and Tumor Spread Through Air Spaces in Resected Non-small Cell Lung Cancer. H. KURODA, K. MASAGO, Y. TAKAHASHI, S. FUJITA, E. SASAKI, T. NAKADA, N. SAKAKURA, H. NAKANISHI, H. MATSUSHITA, Y. YATABE (<i>Nagoya; Tokyo, Japan</i>).....	5499
<i>Clinical Studies</i>	
Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification. Y. MA, X. LIANG, L. LIU, D. GAO, T. YANG, R.M. HOFFMAN, J. XU (<i>Xuzhou; Nanjing, PR China; San Diego, CA, USA</i>)	5507
The Automatically Analyzed (AA) ColonView (CV) Quick Test for Fecal Occult Blood Shows Higher Diagnostic Accuracy in Detection of Colorectal Adenoma than Visually Analyzed Tests. J. MEKLIN, M. ESKELINEN, D.P. GUIMARAES, T. SELANDER, T. TIUSANEN, K. SYRJÄNEN, M. ESKELINEN (<i>Kuopio; Helsinki; Kaarina, Finland; Barretos, Brazil</i>)	5517